Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
2024年5月22日 - 5:05AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Schedule
14A
Proxy
Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No. )
Filed
by the Registrant ☒
Filed
by a Party other than the Registrant ☐
Check
the appropriate box:
☐ |
Preliminary Proxy Statement |
|
|
☐ |
Confidential, for Use of the Commission Only (as
permitted by Rule 14a-6(e)(2)) |
|
|
☐ |
Definitive Proxy Statement |
|
|
☒ |
Definitive Additional Materials |
|
|
☐ |
Soliciting Material under § 240.14a-12 |
IMMIX BIOPHARMA, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment
of Filing Fee (Check all boxes that apply):
☒ |
No fee required |
|
|
☐ |
Fee paid previously with
preliminary materials. |
|
|
☐ |
Fee computed on table in
exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11 |
Immix Biopharma (NASDAQ:IMMX)
過去 株価チャート
から 5 2024 まで 6 2024
Immix Biopharma (NASDAQ:IMMX)
過去 株価チャート
から 6 2023 まで 6 2024